Synthesis, Molecular Modeling and Biological Evaluation of Novel Imatinib Derivatives as Anticancer Agents

Abstract Different derivatives of imatinib, the first targeted BCR-ABL fusion tyrosine kinase inhibitor, were synthesized by a 3-step reaction method. Firstly, benzamide derivative was obtained then aryl piperazine groups or morpholine were linked by the SN2 reaction. Lastly, palladium catalyzed C-N coupling reaction was conducted with hetaryl amine groups. The structures of the new compounds were characterized by spectroscopic methods. For quantitative evaluation of the biological activity of the compounds, MTT assays were performed, where four BCR-ABL negative leukemic cell lines (Jurkat, REH, NALM6 and MOLT4), one BCR-ABL+ cell line (K562) and one non-leukemic cell line (Hek293T) were incubated with various concentrations of the derivatives. Although imatinib was specifically designed for the BCR-ABL protein, our results showed that it was also effective on BCR-ABL negative cell lines except for REH cell line. Molecular docking simulations suggest that except for compound 6, the compounds prefer a DFG-out conformation of the ABL kinase domain. Among them, compound 10 has the highest affinity for ABL kinase domain that is close to the affinity of imatinib. The common rings between compound 10 and imatinib adopt exactly the same conformation and same type of interactions in the ATP binding site with the ABL kinase domain.